Education
About Us
Working with TipRanks
Follow Us
Neuphoria Therapeutics (NEUP)
NASDAQ:NEUP
Total Valuation
Neuphoria Therapeutics has a market cap or net worth of $32.65M. The enterprise value is ―.
Market Cap$32.65M
Enterprise Value―
Share Statistics
Neuphoria Therapeutics has 2,357,613 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding2,357,613
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Neuphoria Therapeutics’s return on equity (ROE) is -0.89 and return on invested capital (ROIC) is -74.21%.
Return on Equity (ROE)-0.89
Return on Assets (ROA)-0.56
Return on Invested Capital (ROIC)-74.21%
Return on Capital Employed (ROCE)-0.75
Revenue Per Employee0.00
Profits Per Employee-1.94M
Employee Count8
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Neuphoria Therapeutics is ―. Neuphoria Therapeutics’s PEG ratio is 1.94.
PE Ratio―
PS Ratio0.00
PB Ratio70.92
Price to Fair Value70.92
Price to FCF-84.49
Price to Operating Cash Flow8.21K
PEG Ratio1.94
Income Statement
In the last 12 months, Neuphoria Therapeutics had revenue of 0.00 and earned -15.49M in profits. Earnings per share was -0.10.
Revenue0.00
Gross Profit0.00
Operating Income-17.89M
Pretax Income-15.58M
Net Income-15.49M
EBITDA-17.13M
Earnings Per Share (EPS)-0.10
Cash Flow
In the last 12 months, operating cash flow was 3.43M and capital expenditures 0.00, giving a free cash flow of 3.43M billion.
Operating Cash Flow3.43M
Free Cash Flow3.43M
Free Cash Flow per Share1.45
Dividends & Yields
Neuphoria Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.32
52-Week Price Change326.82%
50-Day Moving Average10.06
200-Day Moving Average6.54
Relative Strength Index (RSI)65.35
Average Volume (3m)83.47K
Important Dates
Neuphoria Therapeutics upcoming earnings date is ―, ―.
Last Earnings Date―
Next Earnings Date―
Ex-Dividend Date―
Financial Position
Neuphoria Therapeutics as a current ratio of 3.45, with Debt / Equity ratio of 0.66%
Current Ratio3.45
Quick Ratio3.45
Debt to Market Cap<0.01
Net Debt to EBITDA0.72
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Neuphoria Therapeutics has paid -87.32K in taxes.
Income Tax-87.32K
Effective Tax Rate<0.01
Enterprise Valuation
Neuphoria Therapeutics EV to EBITDA ratio is -71.67, with an EV/FCF ratio of -83.65.
EV to Sales0.00
EV to EBITDA-71.67
EV to Free Cash Flow-83.65
EV to Operating Cash Flow-83.65
Balance Sheet
Neuphoria Therapeutics has $17.05M in cash and marketable securities with $172.46K in debt, giving a net cash position of $16.87M billion.
Cash & Marketable Securities$17.05M
Total Debt$172.46K
Net Cash$16.87M
Net Cash Per Share$7.16
Tangible Book Value Per Share$0.02
Margins
Gross margin is 96.83%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin96.83%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Neuphoria Therapeutics is $45.67, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$45.67
Price Target Upside229.75% Upside
Analyst ConsensusStrong Buy
Analyst Count3
Revenue Growth Forecast―
EPS Growth Forecast―